Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

56 results about "TRPM8" patented technology

Transient receptor potential cation channel subfamily M (melastatin) member 8 (TRPM8), also known as the cold and menthol receptor 1 (CMR1), is a protein that in humans is encoded by the TRPM8 gene. The TRPM8 channel is the primary molecular transducer of cold somatosensation in humans.

Low molecular weight modulators of the cold menthol receptor trpm8 and use thereof

The invention relates to new types of modulators of the cold menthol receptor TRPM8, to methods of modulating the TRPM8 receptor using these modulators; and in particular the use of the modulators for inducing a sensation of coldness; and also the articles and compositions produced using these modulators.
Owner:BASF AG

Detection and use of low molecular-weight modulators of the cold-menthol receptor trpm8

The invention relates to novel modulators of the cold menthol receptor TRPM8, to a method for modulating the TRPM8 receptor using said modulators; to the use of the modulators for induction of cold sensation; and to objects and means produced using said modulators.
Owner:BASF AG

New application of 6-gingerol

The invention discloses new application of 6-gingerol. The 6-gingerol is used for respectively regulating M8 and V1 subtype transient receptor potential ion channels (short for TRPM8 and TRPV1) of mammals including humans and can be also used for preparing medicaments for treating related diseases, such as cryalgesia allergy, the parkinsonism, painful bladder syndrome, chronic obstructive pulmonary diseases, and the like as well as tumors of skin, the prostate gland, the mammary gland, the lung, the colon, and the like, participated by the ion channels. The action intensity of the 6-gingerol is higher than that of capsaicin.
Owner:INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI

Trpm8 antagonists

ActiveUS20140371276A1High selectivityAdequate pharmacokinetic profileBiocideNervous disorderSelective antagonistNeurodegeneration
The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and / or exhacerbated respiratory disorders and urological disorders.
Owner:DOMPE FARM SPA

New use of methyl liensinine

The invention discloses a new use of methyl liensinine. Methyl liensinine respectively regulates M8 and V1 subtype transient receptor potential ion channels (TRPM8 and TRPV1 for short) of mammal including human, so as to prepare medicine for treating related diseases joined by the ion channels (such as cold hyperalgesia, parkinsonism, nociceptive bladder syndrome, chronic obstructive lung diseaseand tumours of skin, prostate, breast, lung and colon). The action strength of methyl liensinine of the invention is higher than that of menthol.
Owner:INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI

Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort

ActiveUS20150164924A1Exacerbate painBiocideSenses disorderVasomotor symptomDisease
The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; ocular pain and discomfort; heat discomfort; heat stress; flushing and / or night sweats (vasomotor symptoms); post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The applicant has found that localized delivery of DIPA compounds to the upper eyelid and / or facial skin has an alerting and enhancement effect on behavior and can be used to give a cosmetic refreshing look, to mental alertness, to reduce fatigue, and to improve work output. The present discovery also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy, in diagnosis of neuropathic pain, and in study of TRPM8 function.
Owner:IVIEW THERAPEUTICS

Topical analgesic pain relief formulations, manufacture and methods of use thereof

This disclosure relates to natural topical and analgesic pain relief and anti-inflammation compositions and methods to reduce pain and inflammation. This disclosure also relates to the use of cannabinoid compounds in hydrophilic compositions comprised of synthetic and natural plant extract compounds that are multifunctional TRPM8 ion channel agonists, TRPA1 and TRPV1 ion channel antagonists, CGRP antagonists, COX-2 inhibitors and CB1 and CB2 antagonists. In particular, this disclosure relates to a topical analgesic composition comprising at least one synthetic or natural plant extract TRPM8 agonist, at least one synthetic or natural plant extract is a TRPA1 antagonist, and fixed plant seed oil containing Omega-3 fatty acids TRPV1 antagonists and a carrier.
Owner:HOAG GEORGE EDWARD

Topical analgesic pain relief formulations, manufacture and methods of use thereof

This disclosure relates to natural topical and analgesic pain relief and anti-inflammation compositions and methods to reduce pain and inflammation. This disclosure also relates to the use of non-steroidal anti-inflammatory compounds (NSAIDs) in hydrophilic compositions comprised of synthetic and natural plant extract compounds that are multifunctional TRPM8 ion channel agonists, TRPA1 and TRPV1 ion channel antagonists, CGRP antagonists, and COX-2 inhibitors. In particular, this disclosure relates to a topical analgesic composition comprising at least one NSAID, at least one synthetic or natural plant extract TRPM8 agonist, at least one synthetic or natural plant extract is a TRPA1 antagonist, and at least one fixed plant seed oil containing Omega-3 fatty acids TRPV1 antagonists, and a carrier.
Owner:HOAG GEORGE EDWARD

Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; ocular pain and discomfort; heat discomfort; heat stress; flushing and / or night sweats (vasomotor symptoms); post-operative hypothermia; post-anaesthetic shivering; nasal congestion and nasal obstruction; pharyngeal and esophageal discomfort; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The applicant has found that localized delivery of DIPA compounds to the upper eyelid and / or facial skin has an alerting and enhancement effect on behavior and can be used to give a cosmetic refreshing look, to mental alertness, to reduce fatigue, and to improve work output. The present discovery also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy, in diagnosis of neuropathic pain, and in study of TRPM8 function.
Owner:IVIEW THERAPEUTICS

2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, COPD and asthma

The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I).Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and / or exacerbated respiratory disorders and urological disorders.
Owner:DOMPE FARM SPA

Induction of analgesia in neuropathic pain

The present invention relates to agents which are capable of inducing analgesia in chronic neuropathic pain, associated methods and uses thereof. In particular, the present invention provides compounds capable of activating the TRPM8 receptor for the treatment of chronic neuropathic pain.
Owner:THE UNIV COURT OF THE UNIV OF EDINBURGH

Fibrous Structures Comprising Sensates

PendingUS20180280562A1Absorbent padsBandagesFiberTRPM8
Fibrous structures, for example sanitary tissue products, such as toilet tissue, containing one or more sensates, more particularly one or more TRPM8 receptor triggering agents, a sensate composition, for example surface softening composition, comprising one or more TRPM8 receptor triggering agents, and methods for making same are provided.
Owner:THE PROCTER & GAMBLE COMPANY

Sulfamoyl benzoic acid derivatives as trpm8 antagonists

The present invention relates to sulfamoyl benzoic acid derivatives of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.
Owner:RAQUALIA PHARMA INC

Polypeptide complex of TRPM8 and calmodulin and its uses thereof

The present invention discovered that a mammalian TRPM8 binds to calmodulin. The present invention provides a polypeptide complex comprising a cold-menthol receptor (TRPM8) or an active fragment or derivative of TRPM8 and a calmodulin or an active fragment or derivative of calmodulin, and the uses of the polypeptide complex.
Owner:JANSSEN PHARMA NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products